Pegylated Liposomal Doxorubicin: Metamorphosis of an Old Drug into a New Form of Chemotherapy

REFERENCES

• Medical Applications of Liposomes, D. D. Lasic, D. Papahadjopoulos. Elsevier, Amsterdam 1998
   Google Scholar
• Liposomes: Rational Design, A. S. Janoff. Marcel Dekker, New York 1999
   Google Scholar
• Markman M. Disease Management of Solid Tumors and the Emerging Role of Pegylated Liposomal Doxorubicin. Drugs 1997; 54(suppl 4)1–35
   Google Scholar
• Alberts D. S. Single-Agent Pegylated Liposomal Doxorubicin in Cancer: Current Status and Furture Applications. Oncology 1997; 11(suppl 11)1–68
   Google Scholar
• Stealth Liposomes, D. Lasic, F. Martin. CRC Press, Boca Raton 1995
   Google Scholar
• Long Circulating Liposomes, M. C. Woodle, G. Storm. Springer-Verlag, Berlin 1998, and Landes Bioscience; Austin
   Google Scholar
• Papahadjopoulos D., Allen T., Gabizon A. et al. Sterically Stabilized Liposomes: Improvements in Pharmacokinetics and Anti-Tumor Therapeutic Efficacy. Proc. Natl. Acad. Sci. U.S.A. 1991; 88: 11460–11464
   PubMed Web of Science ®Google Scholar
• Haran G., Cohen R., Bar L. K., et al. Transmembrane Ammonium Sulfate Gradients in Liposomes Produce Efficient and Stable Entrapment of Amphipathic Weak Bases. Biochim. Biophys. Acta 1990; 1025: 143–151
   PubMedGoogle Scholar
• Lasic D. D., Frederk P. M., Stuart M. C.A., et al. Gelation of Liposome Interior. A Novel Method for Drug Encapsulation. FEBS Lett. 1992; 312: 255–258
   PubMed Web of Science ®Google Scholar
• Gabizon A., Price D. C., Huberty J., et al. Effect of Liposome Composition and Other Factors on the Targeting of Liposomes to Experimental Tumors: Biodistribution and Imaging Studies. Cancer Res. 1990; 50: 6371–6378
   PubMed Web of Science ®Google Scholar
• Yuan F., Dellian M., Fukumura D., et al. Vascular Permeability in a Human Tumor Xenograft: Molecular Size Dependence and Cutoff Size. Cancer Res. 1995; 55: 3752–3756
   PubMed Web of Science ®Google Scholar
• Gabizon A. A., Barenholz Y., Bialer M. Prolongation of the Circulation Time of Doxorubicin Encapsulated in Liposomes Containing a Polyethylene Glycol-Derivatized Phospholipid: Pharmacokinetic Studies in Rodents and Dogs. Pharm. Res. 1992; 10: 703–708
   Web of Science ®Google Scholar
• Working P. K., Dayan A. D. Pharmacological-Toxicogical Expert Report—Caelyx™ (Stealth® Liposomal Doxorubicin HCl). Hum. Exper. Toxicol. 1996; 15: 752–785
   Web of Science ®Google Scholar
• Gabizon A., Goren D., Horowitz A. T., et al. Long-Circulating Liposomes for Drug Delivery in Cancer Therapy: A Review of Biodistribution Studies in Tumor-Bearing Animals. Adv. Drug Deliv. Rev. 1997; 24: 337–344
   Web of Science ®Google Scholar
• Vaage J., Donovan D., Uster P., et al. Tumor Uptake of Doxorubicin in Polyethylene Glycol-Coated Liposomes and Therapeutic Effect Against a Xenografted Human Pancreatic Carcinoma. Br. J. Cancer 1997; 75: 482–486
   PubMed Web of Science ®Google Scholar
• Gabizon A., Martin F. Polyethylene-Glycol-Coated (Pegylated) Liposomal Doxorubicin- Rationale for Use in Solid Tumors. Drugs 1997; 54(suppl 4): 15–21
   PubMed Web of Science ®Google Scholar
• Gabizon A., Chemla M., Tzemach D., et al. Liposome Longevity and Stability in Circulation: Effects on the In Vivo Delivery to Tumors and Therapeutic Efficacy of Encapsulated Anthracyclines. J. Drug Targeting 1996; 3: 391–398
   PubMed Web of Science ®Google Scholar
• Hong R-L., Huang C-J., Tseng Y-L., et al. Direct Comparison of Liposomal Doxorubicin with or Without Polyethylene Glycol Coating in C-26 Tumor-Bearing Mice: Is Surface Coating with Polyethylene Glycol Beneficial?. Clin. Cancer Res. 1999; 5: 3645–3652
   PubMed Web of Science ®Google Scholar
• Colbern G. T., Hiller A. J., Musterer R. S., et al. Significant Increase in Antitumor Potency of Doxorubicin HCI by Its Encapsulation in Pegylated Liposomes. J. Liposome Res. 1999; 9: 523–538
   Web of Science ®Google Scholar
• Gabizon A. A., Pappo O., Goren D., et al. Preclinical Studies with Doxorubicin Encapsulated in Polyethyleneglycol-Coated Liposomes. J. Liposome Res. 1993; 3: 517–528
   Google Scholar
• Working P. K., Newman M. S., Sullivan T., et al. Reduction of the Cardiotoxicity of Doxorubicin in Rabbits and Dogs by Encapsulation in Long-Circulating Pegylated Liposomes. J. Pharmacol Exp. Ther. 1999; 289: 1128–1133
   PubMed Web of Science ®Google Scholar
• Gabizon A., Catane R., Uziely B., et al. Prolonged Circulation Time and Enhanced Accumulation in Malignant Exudates of Doxorubicin Encapsulated in Polyethylene-Glycol Coated Liposomes. Cancer Res. 1994; 54: 987–992
   PubMed Web of Science ®Google Scholar
• Martin F. J. Pegylated Liposomal Doxorubicin: Scientific Rationale and Preclinical Pharmacology. Oncology 1997; 11(suppl 11)11–32
   Google Scholar
• Amantea M. A., Forrest A., Northfelt D. W., et al. Population Pharmacokinetics and Pharmacodynamics of Pegylated Liposomal Doxorubicin in Patients with AIDS-Related Kaposi's Sarcoma. Clin. Pharmacol. Ther. 1997; 61: 301–311
   PubMed Web of Science ®Google Scholar
• Lyass O., Uziely B., Ben-Yosef R., et al. Correlation of Toxicity with Pharmacokinetics of Pegylated Liposomal Doxorubicin (Doxil) in Metastatic Breast Cancer. Cancer 2000; 89: 1037–1047
   PubMed Web of Science ®Google Scholar
• Northfelt D. W., Martin F. J., Working P., et al. Doxorubicin Encapsulated in Liposomes Containing Surface-Bound Polyethylene Glycol: Pharmacokinetics, Tumor Localization, and Safety in Patients with AIDS-Related Kaposi's Sarcoma. J. Clin. Pharmacol. 1996; 36: 55–63
   PubMed Web of Science ®Google Scholar
• Stewart S., Harrington K. J. The Biodistribution and Pharmacokinetics of Stealth Liposomes in Patients with Solid Tumors. Oncology 1997; 11(suppl 11)33–37
   Google Scholar
• Symon Z., Peyser A., Tzemach D., et al. Selective Delivery of Doxorubicin to Patients with Breast Carcinoma Metastases by Stealth Liposomes. Cancer 1999; 86: 72–78
   PubMed Web of Science ®Google Scholar
• Uziely B., Jeffers S., Isacson R., et al. Liposomal Doxorubicin: Antitumor Activity and Unique Toxicities During Two Complementary Phase I Studies. J. Clin. Oncol. 1995; 13: 1777–1785
   PubMed Web of Science ®Google Scholar
• Ranson M. R., Carmichael J., O'Byrne K., et al. Treatment of Advanced Breast Cancer with Sterically-Stabilized Liposomal Doxorubicin: Results of a Multicenter Phase II Trial. J. Clin. Oncol. 1997; 15: 3185–3191
   PubMed Web of Science ®Google Scholar
• Muggia F. M., Hainsworth J. D., Jeffers S., et al. Phase II Study of Liposomal Doxorubicin in Refractory Ovarian Cancer: Antitumor Activity and Toxicity Modification by Liposomal Encapsulation. J. Clin. Oncol. 1997; 15: 987–993
   PubMed Web of Science ®Google Scholar
• Hamilton A., Coleman R., Mauriac L., et al. EORTC 10968: Phase I Study of Caelyx at Six Week Intervals in Patients with Metastatic Breast Cancer. Breast Cancer Res. Treat. 1998; 50: 324, abstract
   Google Scholar
• Gabizon A. A., Muggia F. M. Initial Clinical Evaluation of Pegylated Liposomal Doxorubicin in Solid Tumors. Long-Circulating Liposomes: Old Drugs, New Therapeutics, M. C. Woodle, G. Storm. Landes Bioscience, Austin, TX 1998; 165–174
   Google Scholar
• Skubitz K. M., Skubitz A. P.N. Mechanism of Transient Dyspnea Induced by Pegylated-Liposomal Doxorubicin (Doxil™. Anti-Cancer Drugs 1998; 9: 45–50
   PubMed Web of Science ®Google Scholar
• Szebeni J., Wassef N. M., Spielberg H., et al. Complement Activation in Rats by Liposomes and Liposome-Encapsulated Hemoglobin: Evidence for Anti-Lipid Antibodies and Alternate Pathway Activation. Biochem. Biophys. Res. Commun. 1994; 205: 255–263
   PubMed Web of Science ®Google Scholar
• Hubert A., Lyass O., Pode D., et al. Doxil (Caelyx): An Exploratory Study with Pharmacokinetics in Patients with Hormone-Refractory Prostate Cancer. Anti-Cancer Drugs 2000; 11: 123–127
   PubMed Web of Science ®Google Scholar
• Huang S. K., Stauffer P. R., Hong K., et al. Liposomes and Hyperthermia in Mice: Increased Tumor Uptake and Therapeutic Efficacy of Doxorubicin in Sterically Stabilized Liposomes. Cancer Res. 1994; 54: 2186–2191
   PubMed Web of Science ®Google Scholar
• Conley B. A., Egorin M. J., Whitacre M. Y., et al. Phase I and Pharmacokinetic Trial of Liposome-Encapsulated Doxorubicin. Cancer Chemother. Pharmacol. 1993; 33: 107–112
   PubMed Web of Science ®Google Scholar
• Gill P. S., Espina B. M., Muggia F., et al. Phase I/II Clinical and Pharmacokinetic Evaluation of Liposomal Daunorubicin. J. Clin. Oncol. 1995; 13: 996–1003
   PubMed Web of Science ®Google Scholar
• Vail D. M., Chun R., Thamm D. H., et al. Efficacy of Pyridoxine to Ameliorate the Cutaneous Toxicity Associated with Doxorubicin-Containing Pegylated (Stealth) Liposomes: A Randomized, Double-Blind Clinical Trial Using a Canine Model. Clin. Cancer Res. 1998; 4: 1567–1571
   PubMed Web of Science ®Google Scholar
• Berry G., Billingham M., Alderman E., et al. The Use of Cardiac Biopsy to Demonstrate Reduced Cardiotoxicity in AIDS Kaposi's Sarcoma Patients Treated with Pegylated Liposomal Doxorubicin. Ann. Oncol. 1998; 9: 711–716
   PubMed Web of Science ®Google Scholar
• Safra T., Muggia F., Jeffers S., et al. Pegylated Liposomal Doxorubicin (Doxil): Reduced Clinical Cardiotoxicity in Patients Reaching or Exceeding Cumulative Doses of 500 mg/m2. Ann. Oncol. 2000; 11: 1029–1033
   PubMed Web of Science ®Google Scholar
• Madhavan S., Northfelt D. W. Lack of Vesicant Injury Following Extravasation of Liposomal Doxorubicin. J. Natl. Cancer Inst. 1995; 87: 1556–1557
   PubMed Web of Science ®Google Scholar
• Lokich J. Doxil Extravasation Injury: A Case Report. Ann. Oncol. 1999; 10: 735–736
   PubMed Web of Science ®Google Scholar
• Simpson J. K., Miller R. F., Spittle M. F. Liposomal Doxorubicin for Treatment of AIDS-Related Kaposi's Sarcoma. Clin. Oncol. 1993; 5: 372–374
   PubMedGoogle Scholar
• Harrison M., Tomlinson D., Stewart S. Liposomal-Entrapped Doxorubicin: An Active Agent In Aids-Related Kaposi's Sarcoma. J. Clin. Oncol. 1995; 13: 914–920
   PubMed Web of Science ®Google Scholar
• Northfelt D. W., Dezube B. J., Thommes J. A., et al. Pegylated Liposomal Doxorubicin Versus Doxorubicin, Bleomycin and Vincristine in the Treatment of AIDS- Related Kaposi's Sarcoma: Results of a Randomized Phase III Clinical Trial. J. Clin. Oncol. 1998; 16: 2445–2451
   PubMed Web of Science ®Google Scholar
• Stewart S., Jablonowski H., Goebel F. D., et al. Randomized Comparative Trial of Pegylated Liposomal Doxorubicin Versus Bleomycin and Vincristine in the Treatment of AIDS-Related Kaposi's Sarcoma. J. Clin. Oncol. 1998; 16: 683–691
   PubMed Web of Science ®Google Scholar
• Gill P. S., Wernz J., Scadden D. T., et al. Randomized Phase III Trial of Liposomal Daunorubicin Versus Doxorubicin, Bleomycin, and Vincristine in AIDS-Related Kaposi's Sarcoma. J. Clin. Oncol. 1996; 14: 2353–2364
   PubMed Web of Science ®Google Scholar
• Northfelt D. W., Dezube B. J., Thommes J. A., et al. Efficacy of Pegylated-Liposomal Doxorubicin in the Treatment of AIDS-Related Kaposi's Sarcoma After Failure of Standard Chemotherapy. J. Clin. Oncol. 1997; 15: 653–659
   PubMed Web of Science ®Google Scholar
• Gordon A. N., Fleagle J. T., Guthrie D., et al. Interim Analysis of a Phase III Randomized Trial of Doxil/Caelyx Versus Topotecan in the Treatment of Patients with Relapsed Ovarian Cancer. Proc. Am. Soc. Clin. Oncol. 2000; 19: 1504, abstract
   Google Scholar
• Klein P., Hamilton A., Lyass O., et al. Phase I Studies of Doxil Combined with Cisplatin: Efficacy in Epithelial Ovarian and Fallopian Tube Cancers. Proc. Am. Soc. Oncol. 2000; 19: 410a, abstract
   Google Scholar
• Wollina U., Graefe T., Karte K. Treatment of Relapsing or Recalcitrant Cutaneous T-cell Lymphoma with Pegylated Liposomal Doxorubicin. J. Am. Acad. Dermatol. 2000; 42: 40–46
   PubMed Web of Science ®Google Scholar
• Halm U., Etzrodt G., Schiefke I., et al. A Phase II Study of Pegylated Liposomal Doxorubicin for Treatment of Advanced Hepatocellular Carcinoma. Ann. Oncol. 2000; 11: 113–114
   PubMed Web of Science ®Google Scholar
• Ellerhorst J. A., Bedikian A., Ring S., et al. Phase II Trial of Doxil for Patients with Metastatic Melanoma Refractory to Frontline Therapy. Oncol. Rep. 1999; 6: 1097–1099
   PubMed Web of Science ®Google Scholar
• Garcia A. A., Kempf R. A., Rogers M., et al. A Phase II Study of Doxil (Liposomal Doxorubicin): Lack of Activity in Poor Prognosis Soft Tissue Sarcomas. Ann. Oncol. 1998; 9: 1131–1133
   PubMed Web of Science ®Google Scholar
• Judson I., Radford J., Blay J-Y., et al. A Randomised Phase II Trial of Caelyx®/Doxil® Versus Doxorubicin in Advanced or Metastatic Soft Tissue Sarcomas (STS)—An EORTC Soft Tissue and Bone Sarcoma Group (STBSG) Trial. Proc. Am. Soc. Clin. Oncol. 1999; 18: 541a, abstract
   Google Scholar
• Caponigro F., Comella P., Budillon A., et al. Phase I Study of Caelyx (Doxorubicin HCL, Pegylated Liposomal) in Recurrent or Metastatic Head and Neck Cancer. Ann. Oncol. 2000; 11: 339–342
   PubMed Web of Science ®Google Scholar
• Cosgriff T. M., Black M. L., Stein W., III. Successful Treatment of Severe Refractory Idiopathic Thrombocytopenic Purpura with Liposomal Doxorubicin. Am. J. Hematol. 1998; 57: 85–86
   PubMed Web of Science ®Google Scholar
• Lyass O., Hubert A., Tzemach D., et al. Phase I Trial of Doxil Plus Cisplatin in Patients with Advanced Malignancies. Eur. J. Cancer 1999; 35(suppl 4)S287, abstract ECCO
   Google Scholar
• Langley R. E., Carmichael J., Woll P. J., et al. Phase II Trial to Evaluate the Safety and Tolerability of Caelyx® (Doxil®) in Combination with Paclitaxel in the Treatment of Metastatic Cancer. Proc. Am. Soc. Clin. Oncol. 1998; 17: 246a, abstract
   Google Scholar
• Wasserheit C., Downey A., Sorich J., et al. A Phase I Study of Taxotere and Doxil in Patients with Advanced Malignancies. Proc. Am. Soc. Clin. Oncol. 1999; 18: 167a, abstract
   Web of Science ®Google Scholar
• Burstein H. J., Ramirez M. J., Petros W. P., et al. Phase I Study of Doxil and Vinorelbine in Metastatic Breast Cancer. Ann. Oncol. 1999; 10: 1113–1116
   PubMed Web of Science ®Google Scholar
• Lokich J., Bothe A., Zipoli T., et al. Constant Infusion Schedule for Adriamycin: A Phase I-II Clinical Trial of a 30-Day Schedule by Ambulatory Pump Delivery System. J. Clin. Oncol. 1983; 1: 24–28
   PubMed Web of Science ®Google Scholar
• Samuels B. L., Vogelzang N. J., Ruane M., et al. Continuous Venous Infusion of Doxorubicin in Advanced Sarcomas. Cancer Treat. Rep. 1987; 71: 971–972
   PubMedGoogle Scholar
• Krishna R., Mayer L. D. The Use of Liposomal Anticancer Agents to Determine the Roles of Drug Pharmacodistribution and P-Glycoprotein (PGP) Blockade in Overcoming Multidrug Resistance (MDR). Anticancer Res. 1999; 19: 2885–2891
   PubMed Web of Science ®Google Scholar
• Cabanes A., Even-Chen S., Zimberoff J., et al. Enhancement of Antitumor Activity of Polyethylene Glycol-Coated Liposomal Doxorubicin with Soluble and Liposomal Interleukin-2. Clin. Cancer Res. 1999; 5: 687–693
   PubMed Web of Science ®Google Scholar
• Colbern G. T., Hiller A. J., Musterer R. S., et al. Antitumor Activity of Herceptin™ in Combination with Doxil® or Nonencapsulated Doxorubicin in a HER2 Positive Breast Cancer Model. Breast Cancer Res. Treat. 1998; 50: 320, abstract
   Google Scholar
• Koukourakis M. I., Koukouraki S., Giatromanolaki A., et al. Liposomal Doxorubicin and Conventionally Fractionated Radiotherapy in the Treatment of Locally Advanced Non-Small-Cell Lung Cancer and Head and Neck Cancer. J. Clin. Oncol. 1999; 17: 3512–21
   PubMed Web of Science ®Google Scholar
• Lopez de Menezes D. E., Pilarski L. M., Allen T. M. In Vitro and In Vivo Targeting of Immunoliposomal Doxorubicin to Human B-Cell Lymphoma. Cancer Res. 1998; 58: 3320–3330
   PubMed Web of Science ®Google Scholar
• Wang S., Low P. S. Folate-Mediated Targeting of Antineoplastic Drugs, Imaging Agents, and Nucleic Acids to Cancer Cells. J. Controlled Release 1998; 53: 39–48
   PubMed Web of Science ®Google Scholar
• Park J. W., Hong K., Carter P., et al. Development of Anti-p185HER2 Immunoliposomes for Cancer Therapy. Proc. Natl. Acad. Sci. U.S.A. 1995; 92: 1327–1331
   PubMed Web of Science ®Google Scholar
• Goren D., Horowitz A. T., Zalipsky S., et al. Targeting of Stealth Liposomes to erbB2 (Her/2) Receptor: In Vitro and In Vivo Studies. Br. J. Cancer 1996; 74: 1749–1756
   PubMed Web of Science ®Google Scholar
• Gabizon A., Amselem S., Goren D., et al. Preclinical and Clinical Experience with a Doxorubicin-Liposome Preparation. J. Liposome Res. 1990; 1: 491–502
   Google Scholar
• Martin F. J. Clinical Pharmacology and Anti-Tumor Efficacy of Doxil (Pegylated Liposomal Doxorubicin). Medical Applications of Liposomes, D. D. Lasic, D. Papahadjopoulos. Elsevier, New York 1998; 638
   Google Scholar
• Martin F. J. Medical Applications of Liposomes, D. D. Lasic, D. Papahadjopoulos. Elsevier, New York 1998; 654
   Google Scholar